Case Report| Volume 17, ISSUE 2, P157-160, April 2019

Metronomic Oral Cyclophosphamide in 2 Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report

  • Hang Huong Ling
    Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung Branch, Taiwan
    Search for articles by this author
  • Yung-Chang Lin
    Address for correspondence: Yung-Chang Lin, MD, Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan Branch, 333, No. 5, Fu-Shin Street, Queishan District, Taoyuan City, Taiwan
    Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan Branch, Taiwan

    School of Medicine, Chang Gung University, Taoyuan City, Taiwan
    Search for articles by this author
Published:December 18, 2018DOI:
      Approximately 25% of patients with metastatic castration resistant prostate cancer (mCRPC) have sporadic homologous recombination deficiency (HRD) mutations, with 8% being germline mutations.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • de Bono J.S.
        • Logothetis C.J.
        • Molina A.
        • et al.
        • COU-AA-301 Investigators
        Abiraterone and increased survival in metastatic prostate cancer.
        N Engl J Med. 2011; 364: 1995-2005
        • Scher H.I.
        • Fizazi K.
        • Saad F.
        • et al.
        • AFFIRM Investigators
        Increased survival with enzalutamide in prostate cancer after chemotherapy.
        N Engl J Med. 2012; 367: 1187-1197
        • Robinson D.
        • Van Allen E.M.
        • Wu Y.M.
        • et al.
        Integrative clinical genomics of advanced prostate cancer.
        Cell. 2015; 161: 1215-1228
        • Castro E.
        • Goh C.
        • Olmos D.
        • et al.
        Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
        J Clin Oncol. 2013; 31: 1748-1757
        • Mateo J.
        • Carreira S.
        • Sandhu S.
        • et al.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708
        • Pomerantz M.M.
        • Spisák S.
        • Jia L.
        • et al.
        The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
        Cancer. 2017; 123: 3532-3539
        • Deans A.J.
        • West S.C.
        DNA interstrand crosslink repair and cancer.
        Nat Rev Cancer. 2011; 11: 467-480
        • Sharma P.
        • Barlow W.E.
        • Godwin A.K.
        • et al.
        Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
        Ann Oncol. 2018; 29: 654-660
        • Ladoire S.
        • Eymard J.C.
        • Zanetta S.
        • et al.
        Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
        Anticancer Res. 2010; 30: 4317-4323
        • Yashi M.
        • Nishihara D.
        • Mizuno T.
        • et al.
        Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
        Clin Genitourin Cancer. 2014; 12: e197-e203
        • Barroso-Sousa R.
        • da Fonseca L.G.
        • Souza K.T.
        • et al.
        Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
        Med Oncol. 2015; 32: 443
        • Scher H.I.
        • Halabi S.
        • Tannock I.
        • et al.
        Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
        J Clin Oncol. 2008; 26: 1148-1159
        • Bono J.S.D.
        • Hussain M.
        • Thiery-Vuillemin A.
        • et al.
        PROfound: a randomized phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.
        J Clin Oncol. 2017; 35: TPS5091
        • Kellokumpu-Lehtinen P.L.
        • Harmenberg U.
        • Joensuu T.
        • et al.
        2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
        Lancet Oncol. 2013; 14: 117-124
        • Matsumoto K.
        • Tanaka N.
        • Hayakawa N.
        • et al.
        Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.
        Med Oncol. 2013; 30: 717
        • Ciccarese C.
        • Massari F.
        • Iacovelli R.
        • et al.
        Prostate cancer heterogeneity: discovering novel molecular targets for therapy.
        Cancer Treat Rev. 2017; 54: 68-73
        • Robson M.
        • Im S.A.
        • Senkus E.
        • et al.
        Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.
        N Engl J Med. 2017; 377: 523-533
        • Ledermann J.
        • Harter P.
        • Gourley C.
        • et al.
        Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
        N Engl J Med. 2012; 366: 1382-1392
        • Lord R.
        • Nair S.
        • Schache A.
        • et al.
        Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
        J Urol. 2007; 177 (discussion: 2140): 2136-2140
        • Nelius T.
        • Rinard K.
        • Filleur S.
        Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.
        Cancer Treat Rev. 2011; 37: 444-455
        • Dickinson P.D.
        • Peel D.N.Y.
        • Sundar S.
        Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate.
        Br J Cancer. 2012; 106: 1464-1465
        • Raghavan D.
        • Cox K.
        • Pearson B.S.
        • et al.
        Oral cyclophosphamide for the management of hormone-refractory prostate cancer.
        Br J Urol. 1993; 72: 625-628
        • Nelius T.
        • Klatte T.
        • de Riese W.
        • et al.
        Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.
        Med Oncol. 2010; 27: 363-367
        • Hatano K.
        • Nonomura N.
        • Nishimura K.
        • et al.
        Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.
        Jpn J Clin Oncol. 2011; 41: 253-259
        • Gebbia V.
        • Serretta V.
        • Borsellino N.
        • et al.
        Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
        Urology. 2011; 78: 1125-1130
        • Meng L.J.
        • Wang J.
        • Fan W.F.
        • et al.
        Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.
        J Cancer Res Clin Oncol. 2012; 138: 333-339
        • Laber D.A.
        • Chen M.B.
        • Jaglal M.
        • et al.
        Phase 2 study of cyclophosphamide, etoposide, and estramustine in patients with castration-resistant prostate cancer.
        Clin Genitourin Cancer. 2018; 16: 473-481
        • Cheng H.H.
        • Pritchard C.C.
        • Boyd T.
        • et al.
        Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer.
        Eur Urol. 2016; 69: 992-995
        • Wu Y.-M.
        • Cieślik M.
        • Lonigro R.J.
        • et al.
        Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer.
        Cell. 2018; 173: 1770-1782.e14